
Auteur R. AYRES
|
Documents disponibles écrits par cet auteur (5)

Nouveauté
J. M. KESTEN ; R. AYRES ; J. NEALE ; J. CLARK ; P. VICKERMAN ; M. HICKMAN ; S. REDWOOD | 2017
Dans International Journal of Drug Policy (Vol.39, January 2017) Article : PériodiqueBackground: It is recommended that needle and syringe programmes (NSP) distribute low dead space syringes (LDSS) to reduce blood-borne virus transmission. We explored the acceptability of detachable LDSS among people who inject drugs (PWID) and [...]
R. AYRES ; INGRAM J. ; R. GREENWOOD | 2003
Dans Journal of Substance Use (Vol.8 n°2, 2003) Article : PériodiqueENGLISH : Background. The Relapse Avoidance Programme (RAP) at Bristol Drugs Project is a community-based cognitive-behavioural programme that forms part of the services offered by the project. This paper reports an audit of the outcomes of th[...]
E. HANCOCK ; Z. WARD ; R. AYRES ; J. NEALE ; D. HUSSEY ; J. M. KESTEN ; M. HICKMAN ; P. VICKERMAN | 2020
Dans Addiction (Vol.115, n°4, April 2020) Article : PériodiqueBACKGROUND AND AIMS: Traditional detachable syringes used by people who inject drugs (PWID) retain larger volumes of blood when the plunger is depressed than syringes with fixed needles-referred to as high (HDSS) and low dead space syringes (LDS[...]
S. SWEENEY ; Z. WARD ; L. PLATT ; L. GUINNESS ; M. HICKMAN ; V. HOPE ; L. MAHER ; J. IVERSEN ; S. J. HUTCHINSON ; J. SMITH ; R. AYRES ; I. HAINEY ; P. VICKERMAN | 2019
Dans Addiction (Vol.114, n°3, March 2019) Article : PériodiqueAIM: To evaluate the cost-effectiveness of needle and syringe programmes (NSPs) compared with no NSPs on hepatitis C virus (HCV) transmission in the United Kingdom. DESIGN: Cost-effectiveness analysis from a National Health Service (NHS)/healt[...]
Z. WARD ; L. PLATT ; S. SWEENEY ; V. D. HOPE ; L. MAHER ; S. HUTCHINSON ; N. PALMATEER ; J. SMITH ; N. CRAINE ; A. TAYLOR ; N. MARTIN ; R. AYRES ; J. DILLON ; M. HICKMAN ; P. VICKERMAN | 2018
Dans Addiction (Vol.113, n°9, September 2018) Article : PériodiqueAims: To estimate the impact of existing high-coverage needle and syringe provision (HCNSP, defined as obtaining more than one sterile needle and syringe per injection reported) and opioid substitution therapy (OST) on hepatitis C virus (HCV) tr[...]